Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. Cho M, et al. Among authors: sorscher s. HPB (Oxford). 2015 Jul;17(7):587-93. doi: 10.1111/hpb.12413. Epub 2015 Mar 20. HPB (Oxford). 2015. PMID: 25800066 Free PMC article. Clinical Trial.
EGFR mutations and sensitivity to gefitinib.
Sorscher SM. Sorscher SM. N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. doi: 10.1056/NEJM200409163511221. N Engl J Med. 2004. PMID: 15371587 No abstract available.
Coexisting KRAS and NRAS mutations in colon cancer.
Sorscher S. Sorscher S. J Clin Pathol. 2015 Dec;68(12):1044. doi: 10.1136/jclinpath-2015-203259. Epub 2015 Aug 4. J Clin Pathol. 2015. PMID: 26243064 No abstract available.
Mitigating fear of cancer recurrence.
Sorscher S. Sorscher S. Breast Cancer Res Treat. 2023 Apr;198(2):401. doi: 10.1007/s10549-022-06824-9. Epub 2023 Feb 3. Breast Cancer Res Treat. 2023. PMID: 36737585 No abstract available.
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. Wang-Gillam A, et al. Among authors: sorscher s. Invest New Drugs. 2013 Jun;31(3):707-13. doi: 10.1007/s10637-012-9866-y. Epub 2012 Aug 4. Invest New Drugs. 2013. PMID: 22864469 Free PMC article. Clinical Trial.
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Peddi PF, et al. Among authors: sorscher sm. JOP. 2012 Sep 10;13(5):497-501. doi: 10.6092/1590-8577/913. JOP. 2012. PMID: 22964956 Free article. Clinical Trial.
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P. Myerson RJ, et al. Among authors: sorscher s. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):829-36. doi: 10.1016/j.ijrobp.2013.12.028. Int J Radiat Oncol Biol Phys. 2014. PMID: 24606849 Free PMC article. Clinical Trial.
161 results